STUDY QUESTION: Does phthalate exposure from prescription drugs affect semen quality?
Introduction
The increasing prevalence of poor semen quality is a global problem, causing concern over male fertility (Swan et al., 2000; Jørgensen et al., 2012; Romero-Otero et al., 2015; Centola et al., 2016) . Consequently, the need for ART and IUI has increased in Europe and the USA (Swan et al., 2000; Jensen et al., 2008; Danish Fertility Society, 2014; Kupka et al., 2014) .
In recent years, researchers have investigated the possible role of environmental endocrine disruptors, which are thought to affect semen quality (Bay et al., 2006; Rouiller-Fabre et al., 2014; Hauser et al., 2015; Le Moal et al., 2015) . Ortho-phthalates and their metabolites are endocrine disruptors that have been shown to affect hormone signalling in animal models. Of specific interest is their anti-androgenic effects, resulting in decreased anogenital distance, hypospadias, cryptorchidism, decreased testosterone levels, decreased sperm production and infertility (Borch et al., 2006; Foster, 2006; Howdeshell et al., 2008) . Several epidemiologic studies have shown associations between low-level environmental phthalate exposure (quantified by urinary phthalate biomarkers) and poor semen quality, suggesting similar effects in humans (Skakkebaek et al., 2001; Hauser, 2008; Kay et al., 2014; Axelsson et al., 2015; Bloom et al., 2015; Cai et al., 2015) . However, phthalates are rapidly metabolized and excreted in both urine and faeces. Therefore, the use of biomarkers for comparing relative exposure levels to various phthalates could be misleading (Hauser and Calafat, 2005) .
Not commonly recognized, a number of oral drug formulations contain ortho-phthalates and polymers as excipients to enable timed release of the active agent (Hauser et al., 2004; Hernández-Díaz et al., 2009; Gallinger and Nguyen, 2013) . Chronic users of ortho-phthalate containing medications have substantially higher urinary concentration of phthalate metabolites-50-fold or more-compared with the general population (Hauser et al., 2004; Hernández-Díaz et al., 2009) . In contrast to environmental exposure, exposure from a medicinal product is in principle readily avoidable. In case of documented negative influences on human reproduction from medicinal product exposures, this could have regulatory consequences.
Danish nationwide registries, including data on phthalate content in pharmaceuticals, offer a unique opportunity to study the association between exposure to phthalates through medicinal products and selected outcomes. In this article, we investigate the association between medicinal phthalate exposure and semen quality within a cohort referred to ART.
Materials and Methods
In this case-control study, we included all Danish couples registered in the Danish IVF register (IVF-R) during the period 1 January 2006 to 31 December 2016.
Data sources and linkage
Data were obtained from four population-based registries: The IVF-R (Andersen et al., 1999) , the Danish National Patient Registry (DNPR) (Schmidt et al., 2015) , the Danish CPR registry (Schmidt et al., 2014) and the Danish Register of Medicinal Product Statistics (the Prescription Registry) (Pottegård et al., 2016) . Data on drug excipients were retrieved from the Danish Medicines Agency and linked to data from the Prescription Registry. All data sources were linked by use of a unique personal registration number (Pedersen, 2011) . For detailed registry declarations, please see Supplementary Data.
Patient material
The IVF-R contains data on all fertility treatments (including both ART and IUI) performed in Denmark in both private and public clinics. All heterosexual couples were categorized as male factor, female factor, both or idiopathic infertility based on data from both the IVF-R and the DNPR. Female infertility was based on diagnoses [defined by the 8th and 10th version of the International Classification of Diseases (ICD-8/ICD-10)] relevant for female fecundity and included: endometriosis, uterine fibroma, ovarian dysfunction and female infertility (Supplementary Data: ICD codes). Male factor infertility was based on their semen sample. Abnormal semen quality was defined by ICD-10 diagnosis N46, including aspermia, azoospermia, oligozoospermia, other male infertility and male infertility unspecified. Males with 'other male infertility' were excluded if an identified reason for infertility were identified (see exclusions). Normal semen quality was defined as either registered idiopathic infertility or a normal semen sample. Additional male data included age, and information on smoking, alcohol consumption, and BMI. Comorbidities and drug exposure relevant for male fecundity were identified in the IVF-R, the DNPR and the Prescription Registry.
Identification of cases and controls
Cases were defined as all males with reduced semen quality, regardless of any identified female factors. Restricted case definitions were employed for sensitivity analyses: males with reduced semen quality in couples without any female factors as identified in the IVF-R; and males with reduced semen quality in couples without any female factors identified in either the IVF-R or in the DNPR. Controls were identified as all males with normal semen quality who did not meet any of the exclusion criteria.
Exclusions
We excluded couples who did not live in Denmark for at least 12 months before their first fertility treatment and to ensure the date of semen sampling was the same as the date of treatment, we limited the analysis to each couple's first completed IUI or aspiration, excluding all treatments with frozen eggs. Couples referred for PGD, and couples diagnosed with HIV, hepatitis B or hepatitis C were excluded, as were males with a diagnosis of cancer (except skin cancer), retrograde ejaculation, testicular or epididymal sperm extraction, or previous sterilization. Lastly, if a male recurred with more partners in the registry, any treatments with later partners were excluded. A complete list of ICD-8 and ICD-10 codes used for exclusions appears in Supplementary Data.
Study drugs
The Danish Medicines and Health Authorities maintain an internal database with detailed information on specific marketed products, including quantifiable excipient content such as phthalates (The Danish Medicines Authority, 2017). We constructed a dataset listing all medicinal products containing phthalates marketed in Denmark between 2004 and 2016. The dataset includes the Anatomical Therapeutic Chemical (ATC) code for the active substance as defined by the Anatomical Therapeutic Chemical Classification System, the Nordic article number (VNR) for the specific product, the specific phthalate excipient (ortho-phthalates and/or polymers), and the amount used in the specific product formulation. Specific VNR codes for phthalate-containing product formulations, and phthalatefree versions of the same generic products were identified using the ATC code, and merged with prescription records from the Prescription Registry.
Exposure
Exposure was defined as having filled a prescription for a phthalatecontaining product. Five different phthalates were identified and classified into two groups: ortho-phthalates: diethyl phthalate (DEP) and dibutyl phthalate (DBP); polymers: cellulose acetate phthalate (CAP), poly vinyl acetate phthalate (PVAP) and hydroxypropyl methylcellulose phthalate (HPMCP). Phthalate exposure was assumed to start on the day of prescription collection and, with the exception of systemic antibiotics, a standard treatment duration of 90 days was assumed. For antibiotics, we assigned the entire phthalate load to the prescription fill date. Three exposure windows were defined: current (1-90 days), recent (91-180 days) and former (181-365 days) use before the date of first fertility treatment per couple. Only days of exposure overlapping with the exposure window would be accounted for. For subanalyses, an 'immediate' exposure window was defined as 1-10 days prior to the first fertility treatment. Prescriptions redeemed on the day of fertility treatment were ignored. As spermatogenesis takes~70 days (Amann, 2008) , the 'current exposure' definition was of primary interest.
Statistical analyses
Using unconditional logistic regression, we calculated adjusted odds ratios (ORs) associating phthalate exposure with poor semen quality. To address confounding by indication, we compared males exposed to phthalatecontaining prescription drugs to males exposed to phthalate-free versions of the same ATC groups. For minimally adjusted models we included age and year of treatment as covariates. For fully adjusted models we further included previous diagnosis of ≥1 fertility-related comorbidities (Table I) , and prescription for drugs known or suspected to negatively affect male fertility (Table I) . For all drugs, exposure was limited to prescriptions redeemed within 180 days before the first ART. A full list of diagnosis codes used can be found in Supplementary Data. We performed several sensitivity analyses. First, we restricted our study population to cases and controls unexposed to any of these drugs. Second, we changed the comparison group from males exposed to phthalate-free versions of the same ATC groups to males unexposed to prescription drugs.
We calculated the cumulated amount of exposure to each specific phthalate, and for each type of phthalate we calculated the range of exposure and calculated the odds of abnormal semen quality within tertiles of cumulative exposure. For current exposure, we identified males exceeding the daily maximum exposure limits for ortho-phthalates (DEP and DBP) over the entire 90-day window. The exposure limits were set at 4.0 mg/kg body weight/day for DEP, and 0.01 mg/kg body weight/day for DBP, according to European Medicines Agency guidelines (EMA, 2014; Broe et al., 2017) . No exposure limits have been introduced for high molecular weight polymers due to low absorption (Kossor et al., 2014 According to Danish law, ethics approval is not required for register studies.
Results
We identified 59 183 unique heterosexual couples in the IVF registry between 1 January 2006 and 31 December 2016. After applying exclusions, 49 578 unique couples remained in the study (Fig. 1) . The main analyses comprised a total of 18 515 cases with low semen quality (Fig. 2) . For the two case definitions restricted to couples without any female factors we identified a total of 12 634 and 5091 cases, respectively. A total of 31 063 controls were identified and used to represent the at-risk population for all three case definitions. Compared with controls, males with abnormal semen quality had a higher prevalence of fertility-related comorbidities (11.6 versus 5.5%). Adjusting for these comorbidities did not substantially affect ORs that were already adjusted for age and year of treatment. Cases and controls were similarly exposed to drugs with known or suspected effects on fertility (Table I) . Selected demographic characteristics, including alcohol, smoking and BMI, were only sporadically available (Supplementary Table SI) . Table II shows the comparison of males exposed to identical active drugs in formulations with ortho-phthalates and/or polymers, and drugs without phthalates. Current exposure to any of the study products containing ortho-phthalates (upper panel) was, although statistically insignificant, associated with a 30% relative increase in the odds of poor semen quality [adjusted OR of 1.30 (95% CI: 0.91-1.85)], whereas current exposure to any of the study drugs containing polymers (lower panel) was associated with a 71% relative increase in the odds of poor semen quality [adjusted OR of 1.71 (95% CI: 1.24-2.35)]. When comparing males exposed to phthalate-free drugs to males unexposed to prescription drugs, we found an adjusted OR of 1.00 (0.94-1.07), indicating no difference in risk of poor semen quality (data not shown).
Using an exposure window of 90 days yielded an adjusted OR of 1.57 (95% CI: 1.21-2.05) for poor semen quality (Table III) . When restricting to cases and controls who were unexposed to the prescription drugs listed in Table I , we found an adjusted OR of 1.36 (95% CI: 0.99-1.88) for poor semen quality (Supplementary Table SII) .
No clear relationship was found between tertiles of exposure and odds of poor semen quality. Assuming a body weight of 70 kg and an evenly distributed exposure during the 90 days prior to ART, 15 cases and 17 controls exceeded the daily maximum exposure limits (DME) defined by regulatory agencies for DBP of 0.01 mg/kg/day (Supplementary Table SIII) . No males exceeded the DME of 4.0 mg/ kg/day set for DEP.
The highest odds for poor semen quality was found among males chronically exposed to phthalates (Table II) . Results for the two case definitions restricted to couples without any female factors were presented in Supplementary Tables SIV-SVIII.
Discussion
In this unique, large case-control study we found that exposure to medicinal products containing ortho-phthalates or polymers was associated with a decreased sperm quality (OR = 1.32, 95% CI: 0.93-1.87) and (OR = 1.73, 95% CI: 1.26-2.36), respectively. The highest OR was found for exposure to polymers from alimentary tract and metabolism drugs, specifically bisacodyl and sulfasalazine. Stratification per specific phthalate did not yield an obvious pattern. Analysis of cumulative exposure did suggest some cumulative dose-response relationship based on tertile exposure, but the precision of these estimates was poor owing to the low number of cases and controls in each stratum (Supplementary Table SIII) .
Several studies have assessed the association between low-level environmental ortho-phthalate exposure during adulthood and poor semen quality. The vast majority of these comprise patients from fertility clinics, using urinary phthalate metabolite concentrations as markers of environmental exposure (Duty et al., 2003; Hauser et al., 2006 Hauser et al., , 2007 Wirth et al., 2008; Herr et al., 2009; Liu et al., 2012; Jurewicz et al., 2013; Han et al., 2014; Wang et al., 2015 Wang et al., , 2016b Chang et al., 2017) ; while others relied on blood or seminal fluid for exposure characterization (Pant et al., 2014; You et al., 2015; Wang et al., 2016a) . Study subjects comprised healthy young men Axelsson et al., 2015) , partners of pregnant women (Thurston et al., 2015) , or partners of females discontinuing contraception (Bloom et al., 2015) . Joensen et al. (2012) , Thurston et al. (2015) and Bloom et al. (2015) had inconclusive results, while Axelsson et al. (2015) ound an association between phthalate exposure and poor semen quality. All of these studies were based on low environmental sources of exposure and relied fully on biomarkers collected on the date of semen sampling, and are therefore not necessarily reflecting the exposure levels during the period of spermatogenesis.
Only one other research group has evaluated the potential association between phthalate exposure from identified medical products and semen quality. Nassan et al. (2016) designed an interventional crossover-crossback study in males suffering from inflammatory bowel disease. During two times 4 months, patients were exposed to two different formulations of mesalamine; with and without phthalate, respectively. Males unexposed to phthalates at baseline had a decline in semen quality after crossover, and a cumulative carryover effect of the high phthalate exposure into the crossback interval (Nassan et al., 2016) . These observations are in accordance with our findings. For mesalazine, we demonstrate an adjusted OR of 1.70 (0.53-5.45), which, while imprecise, suggests an effect of ortho-phthalate exposure on spermatogenesis. Our results do not suggest that effects differ between ortho-phthalates and polymers. As effects on spermatogenesis are hypothesized to be mediated through anti-androgenic effects of systemically available phthalates, this observation is somewhat unexpected, as polymers are generally not believed to be systemically available to a meaningful extent (Kossor et al., 2014) . Our findings did suggest differences between drug classes, and between sporadic and chronic exposure to phthalate-containing drugs. Cases were more often chronic users of drugs containing polymers, and controls were more often chronic users of ortho-phthalate containing drugs. These findings require further exploration in a larger population sample.
A limitation to our study was the reliance on ICD-10 diagnoses for classification of semen quality. The main level classification is reliable, but sub stratification of semen quality may be less valid. Semen quality is further classified according to sperm concentration, amount of morphologically abnormal spermatozoa, sperm motility, and presence of sperm in ejaculate. Normal values of such parameters are mentioned in five consecutive laboratory manuals published by the World Health  Organization since 1980 (WHO, 2010) . In the 2010 edition, the limit of normal sperm concentration was changed from 20 million/mL to 15 million/mL. Using the ICD-10 codes in Denmark it is not possible to code reduced sperm motility, as this code does not exist, and it is also not possible to classify abnormal morphology without decrease in concentration. The IVF-R is limited to couples attending a fertility clinic, and public referral is restricted to couples unable to conceive after 12 months, unless any obvious cause of infertility is present in either partner. However, we have no reason to believe that phthalate exposure is related to the decision of fertility treatment or not. When identifying the control group, we assumed that a normal semen sample would imply normal fertility. However, it is possible that phthalate exposure can affect unmeasured functionality of semen.
To address confounding by indication or active drug ingredients in the prescription drug used to treat their condition, we compared phthalateexposed individuals with males using the same generic drug but in a phthalate-free version. No such confounding was apparent and, somewhat puzzling, we found a null effect when comparing males exposed to phthalate-free drugs to males unexposed to prescription drugs. The Danish reimbursement system in effect is based on the cheapest generic drug. Pharmacies are required by law to offer the patient the cheapest generic version, and phthalate content is unrelated to the product price. For the specific ATC codes, the signal was persistent for alimentary tract and metabolism drugs, while analysis for confounding mitigated the apparent signal from drugs belonging to anti-infectives for systemic use, musculo-skeletal system and nervous system groups. The subgroup analysis is compromised by the low number of cases and controls exposed to the specific individual drug with and without phthalate (Table II) . Furthermore, the sample size did not permit meaningful exploration of specific phthalate exposure and specific semen parameters. Phthalate exposure from environmental sources is unaccounted for. However, the estimated level of exposure from environmental sources is several orders of magnitude lower than quantifiable exposure from drugs, and unlikely to substantially influence our analysis (Hernández-Díaz et al., 2009; Hait et al., 2014) . The analysis comparing exposure to identical active moieties with and without phthalate would also mitigate the influence of environmental exposure.
In conclusion, exposure to drugs containing ortho-phthalates and/ or polymers within 90 days prior to semen sampling was associated with a 30 and 71% increased risk of poor semen quality, respectively. Our findings support a likely negative effect of phthalates exposure on semen quality, and may be of relevance to the regulatory authorities.
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